Log in

NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

$21.03
+1.03 (+5.15 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.12
Now: $21.03
$21.70
50-Day Range
$20.00
MA: $23.94
$26.62
52-Week Range
$11.75
Now: $21.03
$27.68
Volume709,779 shs
Average Volume679,506 shs
Market Capitalization$1.55 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Read More
Dicerna Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.90 million
Book Value$2.22 per share

Profitability

Net Income$-120,460,000.00
Net Margins-213.04%

Miscellaneous

Employees78
Market Cap$1.55 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$21.03
+1.03 (+5.15 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

How has Dicerna Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DRNA shares have increased by 24.6% and is now trading at $21.03.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Dicerna Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Dicerna Pharmaceuticals
.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Dicerna Pharmaceuticals
.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of $0.11 by $0.54. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%.
View Dicerna Pharmaceuticals' earnings history
.

What price target have analysts set for DRNA?

11 equities research analysts have issued twelve-month target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $35.30 in the next year. This suggests a possible upside of 67.9% from the stock's current price.
View analysts' price targets for Dicerna Pharmaceuticals
.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

Media stories about DRNA stock have trended very positive recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Dicerna Pharmaceuticals
.

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a decrease in short interest in June. As of June 30th, there was short interest totaling 2,960,000 shares, a decrease of 7.8% from the June 15th total of 3,210,000 shares. Based on an average daily volume of 639,600 shares, the days-to-cover ratio is presently 4.6 days. Currently, 4.6% of the shares of the company are short sold.
View Dicerna Pharmaceuticals' Current Options Chain
.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Group AG (1.83%), Candriam Luxembourg S.C.A. (1.82%), Emerald Advisers LLC (0.70%), Emerald Mutual Fund Advisers Trust (0.47%), Swiss National Bank (0.19%) and Alps Advisors Inc. (0.14%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky.
View institutional ownership trends for Dicerna Pharmaceuticals
.

Which institutional investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Cadence Capital Management LLC, First Trust Advisors LP, Alps Advisors Inc., WINTON GROUP Ltd, and Hancock Whitney Corp. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky.
View insider buying and selling activity for Dicerna Pharmaceuticals
.

Which institutional investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Swiss National Bank, Rafferty Asset Management LLC, Jennison Associates LLC, Trexquant Investment LP, Principal Financial Group Inc., and Moody Aldrich Partners LLC.
View insider buying and selling activity for Dicerna Pharmaceuticals
.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $21.03.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.55 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.